Showing results (121-130 of 380) with videos related to

Sort By:
Pageof 38
Leukemia & Lymphoma|August 19, 2025
Mortality and relapse dynamics in AML after three years of complete remissionSamuel Urrutia, Wei-Ying Jen, Koji Sasaki, et al.
Cancer Research Communications|February 23, 2024
Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade TherapyJessica L Root, Poonam N Desai, Christopher Ly, et al.
Cancer|August 11, 2016
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phaseKoichi Takahashi, Hagop M Kantarjian, Yulong Yang, et al.
Cancer|October 20, 2015
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitorsKoji Sasaki, Hagop M Kantarjian, Preetesh Jain, et al.
American Journal of Hematology|December 23, 2014
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndromePaolo Strati, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia & Lymphoma|July 26, 2026
Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignanciesNorbert Vey, Olga Salamero, Ashish Bajel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2026
Phase 1 Study of KITE-222, an Autologous CLL-1-directed CAR T-cell Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNaval Daver, James S Blachly, Armin Ghobadi, et al.
Blood Advances|September 23, 2021
Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapyHussein A Abbas, Zoe Alaniz, Sean Mackay, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 30, 2015
Characteristics of Sweet Syndrome in patients with acute myeloid leukemiaSyed M Kazmi, Naveen Pemmaraju, Keyur P Patel, et al.
Cancer Immunology, Immunotherapy : CII|April 10, 2026
A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemiaMarina Konopleva, Vijaya Raj Bhatt, Ioannis Mantzaris, et al.
Pageof 38